KRAS and colorectal cancer: Further analysis of classifiers of the human expression data has also newly identified three classes of pathway derived subtypes (PDS1-3) in colorectal cancer with and without KRAS mutations, where CSM4 and CSM1 combine in the PDS2 subtype where TGF-β-BMP-SMAD4 pathway expression profiles appear enriched4.